Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.
Drug development for metastatic castration-resistant prostate cancer: current status and future perspectives.
复制标题
DOI：
10.2217/fon.11.14
复制
发表时间：
2011-04
期刊：
影响因子：
3.3
通讯作者：
K. Lassi;N. Dawson
中科院分区：
文献类型：
--
作者：
K. Lassi;N. Dawson
前列腺癌占美国男性新诊断癌症的三分之一，2009年估计发病率为192,280例，死亡人数为27,360人。它仍然是癌症相关发病率和死亡率的主要原因，迫切需要新的治疗方法。历史上，以多西他赛为基础的化疗进展后，全身治疗的选择是有限的。这篇文章回顾了目前在转移性去势抵抗性前列腺癌中显示活性的新疗法的数据，以及它们在治疗这种预后不良的疾病中的未来作用。
Prostate cancer represents a third of all newly diagnosed cancers in men in the USA with an estimated incidence of 192,280 cases and 27,360 deaths in 2009. It continues to be a major cause of cancer-related morbidity and mortality, and there is an urgent need for new treatments. Historically, systemic therapy options were limited after progression on docetaxel-based chemotherapy. This article reviews current data on the novel therapeutics demonstrating activity in metastatic castration-resistant prostate cancer and their future role in the treatment of this disease with a poor prognosis.